Aaron L. Zebolsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aaron L. Zebolsky has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Anas Eid
Department of Otolaryngology–Head and Neck Surgery The University of Tennessee Health Science Center Memphis Tennessee USA
5 shared publicationsTravis Clarke
Department of Otolaryngology–Head and Neck Surgery The University of Tennessee Health Science Center Memphis Tennessee USA
5 shared publications- Edgar Ochoa
Department of Otolaryngology‐Head and Neck Surgery University of California‐San Francisco San Francisco California USA
3 shared publications - Philip Daniel Knott
Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA
3 shared publications Chase Heaton
Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology/Head and Neck Surgery University of California, San Francisco San Francisco California U.S.A.
2 shared publicationsChase M. Heaton
Division of Head and Neck Oncologic Surgery, Department of Otolaryngology‐Head & Neck Surgery University of California San Francisco California USA
2 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Wiley in Microsurgery
- Vol. 46 (2)
Jaw‐In‐a‐Day Reconstruction: A Scoping Review of Clinical Outcomes and Evidence Gaps
Background: Jaw‐in‐a‐Day (JIAD) reconstruction—combining osseous free tissue transfer, dental implant placement, and intraoperative prosthesis delivery—provides immediate functional and psychosocial rehabilitation after segmental jaw resection. Despite increasing adoption, the existing evidence remains heterogeneous and inconsistently reported. Methods: A scoping review was conducted following PRISMA‐ScR guidelines. PubMed/MEDLINE was searched through April 2025 for studies reporting true JIAD cases, defined strictly as simultaneous free‐flap reconstruction, implant placement, and intraoperative delivery of a functional prosthesis. Data were extracted on study design, indications, reconstructive methods, prosthetic variables, implant and flap outcomes, soft‐tissue findings, functional recovery, and complications. Results: Thirty‐two studies (2009–2025) met inclusion criteria, describing 274 JIAD patients. Most reports were single‐center case reports or series (77% Level IV–V evidence) and originated from the United States, with publication frequency increasing sharply after 2021. Reconstruction involved the mandible in 82% of cases, predominantly using fibula flaps (> 95%). Immediate prostheses were fixed in 95% and nearly always provisional, with definitive prosthesis typically delivered 3–6 months postoperatively. Implant survival ranged 87.5%–100% across short‐ to mid‐term follow‐up intervals. Maxillary reconstructions and intraoral skin paddles were each associated with increased implant complications in isolated cohorts, but these findings were not replicated. A dedicated series reported peri‐implant reactive tissues in 21% of implants, managed with local soft‐tissue procedures. Flap survival remained high (92%–100%), and functional recovery was typically rapid, although no study employed validated patient‐reported outcome measures. One comparative cohort suggested lower osteoradionecrosis rates when implants were placed before adjuvant radiation, though sample size was small. Conclusions: JIAD reconstruction yields high implant and flap survival with encouraging early functional outcomes. However, the evidence base is limited by small samples, short follow‐up, and inconsistent reporting. Standardized definitions, validated outcome measures, and multicenter prospective studies are needed to clarify long‐term durability and refine patient selection.
- 23 February 2026
- Published by Wiley in Microsurgery
- Vol. 46 (2)
Open AccessJaw‐In‐a‐Day Reconstruction: A Scoping Review of Clinical Outcomes and Evidence Gaps
Background: Jaw‐in‐a‐Day (JIAD) reconstruction—combining osseous free tissue transfer, dental implant placement, and intraoperative prosthesis delivery—provides immediate functional and psychosocial rehabilitation after segmental jaw resection. Despite increasing adoption, the existing evidence remains heterogeneous and inconsistently reported. Methods: A scoping review was conducted following PRISMA‐ScR guidelines. PubMed/MEDLINE was searched through April 2025 for studies reporting true JIAD cases, defined strictly as simultaneous free‐flap reconstruction, implant placement, and intraoperative delivery of a functional prosthesis. Data were extracted on study design, indications, reconstructive methods, prosthetic variables, implant and flap outcomes, soft‐tissue findings, functional recovery, and complications. Results: Thirty‐two studies (2009–2025) met inclusion criteria, describing 274 JIAD patients. Most reports were single‐center case reports or series (77% Level IV–V evidence) and originated from the United States, with publication frequency increasing sharply after 2021. Reconstruction involved the mandible in 82% of cases, predominantly using fibula flaps (> 95%). Immediate prostheses were fixed in 95% and nearly always provisional, with definitive prosthesis typically delivered 3–6 months postoperatively. Implant survival ranged 87.5%–100% across short‐ to mid‐term follow‐up intervals. Maxillary reconstructions and intraoral skin paddles were each associated with increased implant complications in isolated cohorts, but these findings were not replicated. A dedicated series reported peri‐implant reactive tissues in 21% of implants, managed with local soft‐tissue procedures. Flap survival remained high (92%–100%), and functional recovery was typically rapid, although no study employed validated patient‐reported outcome measures. One comparative cohort suggested lower osteoradionecrosis rates when implants were placed before adjuvant radiation, though sample size was small. Conclusions: JIAD reconstruction yields high implant and flap survival with encouraging early functional outcomes. However, the evidence base is limited by small samples, short follow‐up, and inconsistent reporting. Standardized definitions, validated outcome measures, and multicenter prospective studies are needed to clarify long‐term durability and refine patient selection.
- 29 October 2025
- Published by Wiley in Microsurgery
- Vol. 45 (8) , e70133
Efficacy of Indocyanine Green Angiography for Predicting Subclinical Intraoperative Thrombosis During Head and Neck Microvascular Free Tissue Transfer
Background: Traditional intraoperative flap assessments like capillary refill and distal bleeding can provide insight on flap viability and circulation; however, it is difficult to assess the cause of the vascular compromise or detect early “subclinical” thrombosis. This study was designed to determine the sensitivity and specificity of indocyanine green angiography (ICGA) in detecting subclinical intraoperative thrombosis during HN‐MFTT. Methods: A retrospective cohort study was performed on HN‐MFTT cases at a single institution. Flaps where ICGA was employed after completing the anastomosis were reviewed. The frequency of subclinical intraoperative thrombosis was compared between cases with normal and abnormal ICGA prompting vessel exploration. Results: A total of 67 patients who had intraoperative ICGA were included (male, 55 [82.1%]; median age, 64 [interquartile range, 56–72]). Most underwent anterolateral thigh ( n = 56, 83.6%), fibula ( n = 13, 19.4%), or radial forearm ( n = 12, 17.9%) reconstruction. Of the flaps included, 11 (16.5%) had abnormal ICGA and 9 (13.4%) had subclinical thrombosis. For predicting subclinical thrombosis, abnormal ICGA had a sensitivity of 100% (95% CI: 66.4–100), specificity of 96.6% (95% CI: 88.1–99.6), positive predictive value of 81.8% (95% CI: 48.2–97.7), and negative predictive value of 100% (95% CI: 93.6–100). There was no significant difference in takebacks, flap loss, and complications between those with normal and abnormal ICGA ( p > 0.05 for all tests). Conclusion: ICGA is a sensitive and specific technique for detecting intraoperative, subclinical thrombosis during HN‐MFTT in properly selected patients. This warrants future research to define indications for ICGA use and evaluate how this technology affects clinical outcomes.
- 29 October 2025
- Published by Wiley in Microsurgery
- Vol. 45 (8) , e70133
Efficacy of Indocyanine Green Angiography for Predicting Subclinical Intraoperative Thrombosis During Head and Neck Microvascular Free Tissue Transfer
Background: Traditional intraoperative flap assessments like capillary refill and distal bleeding can provide insight on flap viability and circulation; however, it is difficult to assess the cause of the vascular compromise or detect early “subclinical” thrombosis. This study was designed to determine the sensitivity and specificity of indocyanine green angiography (ICGA) in detecting subclinical intraoperative thrombosis during HN‐MFTT. Methods: A retrospective cohort study was performed on HN‐MFTT cases at a single institution. Flaps where ICGA was employed after completing the anastomosis were reviewed. The frequency of subclinical intraoperative thrombosis was compared between cases with normal and abnormal ICGA prompting vessel exploration. Results: A total of 67 patients who had intraoperative ICGA were included (male, 55 [82.1%]; median age, 64 [interquartile range, 56–72]). Most underwent anterolateral thigh ( n = 56, 83.6%), fibula ( n = 13, 19.4%), or radial forearm ( n = 12, 17.9%) reconstruction. Of the flaps included, 11 (16.5%) had abnormal ICGA and 9 (13.4%) had subclinical thrombosis. For predicting subclinical thrombosis, abnormal ICGA had a sensitivity of 100% (95% CI: 66.4–100), specificity of 96.6% (95% CI: 88.1–99.6), positive predictive value of 81.8% (95% CI: 48.2–97.7), and negative predictive value of 100% (95% CI: 93.6–100). There was no significant difference in takebacks, flap loss, and complications between those with normal and abnormal ICGA ( p > 0.05 for all tests). Conclusion: ICGA is a sensitive and specific technique for detecting intraoperative, subclinical thrombosis during HN‐MFTT in properly selected patients. This warrants future research to define indications for ICGA use and evaluate how this technology affects clinical outcomes.
- 16 September 2025
- Published by SAGE Publications in Facial Plastic Surgery & Aesthetic Medicine
- Vol. 28 (1) , 66-73
Measuring the IMPACT: Pilot Validation of a Novel Patient-Reported Outcome Measure for Craniomaxillofacial Trauma
Background: There is a paucity of validated, patient-reported outcome measures for quality-of-life (QOL) in craniomaxillofacial (CMF) trauma. Objective: To determine whether the Integrated Modular Patient-Reported Outcome Assessment for Craniomaxillofacial Trauma (IMPACT) independently measures QOL in patients presenting for routine follow-up within 3 months of injury by comparing with the 15-Dimension QOL survey (15D). Methods: A mixed-methods, pilot validation was performed via literature review, expert opinion, patient interviews, and prospective survey collection. Criterion validity was determined by multivariable adjusted correlation coefficients (B) between IMPACT and 15D scores. Reliability was assessed by Cronbach’s alpha (A). Results: General (IMPACT-G), Nasal (IMPACT-N), Orbit (IMPACT-O), and Jaw (IMPACT-J) modules were developed. Domains include overall satisfaction, facial function, facial appearance, psychosocial function, general symptoms, and pain. Validation was performed in 53 patients with CMF trauma who had mandible ( n = 27, 50.1%), nasal ( n = 10, 18.9%), zygomaticomaxillary complex ( n = 7, 13.2%), Le Fort ( n = 6, 11.3%), and/or other fracture patterns. IMPACT scores independently predicted QOL (B > |0.4|; p < 0.05) and reliability was high (A >0.8; p < 0.05). Conclusions: The IMPACT was developed to measure QOL in patients suffering CMF trauma, and results from this initial validation study warrant expansion to a larger, diversified cohort.
- 16 September 2025
- Published by SAGE Publications in Facial Plastic Surgery & Aesthetic Medicine
- Vol. 28 (1) , 66-73
Measuring the IMPACT: Pilot Validation of a Novel Patient-Reported Outcome Measure for Craniomaxillofacial Trauma
Background: There is a paucity of validated, patient-reported outcome measures for quality-of-life (QOL) in craniomaxillofacial (CMF) trauma. Objective: To determine whether the Integrated Modular Patient-Reported Outcome Assessment for Craniomaxillofacial Trauma (IMPACT) independently measures QOL in patients presenting for routine follow-up within 3 months of injury by comparing with the 15-Dimension QOL survey (15D). Methods: A mixed-methods, pilot validation was performed via literature review, expert opinion, patient interviews, and prospective survey collection. Criterion validity was determined by multivariable adjusted correlation coefficients (B) between IMPACT and 15D scores. Reliability was assessed by Cronbach’s alpha (A). Results: General (IMPACT-G), Nasal (IMPACT-N), Orbit (IMPACT-O), and Jaw (IMPACT-J) modules were developed. Domains include overall satisfaction, facial function, facial appearance, psychosocial function, general symptoms, and pain. Validation was performed in 53 patients with CMF trauma who had mandible ( n = 27, 50.1%), nasal ( n = 10, 18.9%), zygomaticomaxillary complex ( n = 7, 13.2%), Le Fort ( n = 6, 11.3%), and/or other fracture patterns. IMPACT scores independently predicted QOL (B > |0.4|; p < 0.05) and reliability was high (A >0.8; p < 0.05). Conclusions: The IMPACT was developed to measure QOL in patients suffering CMF trauma, and results from this initial validation study warrant expansion to a larger, diversified cohort.
- 15 May 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3498-3507
Patient‐Reported Outcome Measures in Maxillofacial Trauma: A Scoping Review
Objective: The majority of maxillofacial trauma research is limited to objective and clinician‐rated outcome metrics. This review was designed to characterize topic domains of patient‐reported outcome measures (PROMs) previously used in the field.Data Sources: PubMed, Cochrane, Scopus, and CINAHL.Review Methods: Publications through March 2025 reporting at least one PROM in maxillofacial trauma patients were included. Study metadata was recorded, and survey instruments were classified as established PROMs or “custom surveys.” Each instrument was analyzed, and key topic domains were characterized. PRISMA‐ScR guidelines were followed.Results: Ninety‐six studies from 23 different countries were identified. They included patients with mandible fractures (n = 38, 39.6%), midface fractures (n = 16, 16.7%), or both (n = 42, 43.8%). There were 73 studies that used 39 unique, established PROMs. These incorporated six key domains: Psychosocial Function (n = 32, 82.1%), Facial Function (n = 13, 33.3%), Facial Appearance (n = 9, 23.1%), Pain (n = 15, 38.5%), Daily Tasks (n = 14, 35.9%), and Satisfaction with Outcome (n = 5, 12.8%). The most common instruments were the Hospital Anxiety and Depression Scale (HADS), Oral Health Impact Profile (OHIP‐14), Mandible Function Impairment Questionnaire (MFIQ), and the Short Form (SF) survey. Forty studies developed at least one custom survey question. These were more likely to address Facial Function (n = 23, 57.5%), Pain (n = 20, 50%), Facial Appearance (n = 15, 37.5%), and Satisfaction with Outcome (n = 13, 32.5%).Conclusion: PROMs used in maxillofacial trauma research are heterogeneous. Most address psychosocial function while only a minority address facial function and appearance. The six key domains identified here may be used to guide the development of novel PROMs.
- 15 May 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3498-3507
Patient‐Reported Outcome Measures in Maxillofacial Trauma: A Scoping Review
Objective: The majority of maxillofacial trauma research is limited to objective and clinician‐rated outcome metrics. This review was designed to characterize topic domains of patient‐reported outcome measures (PROMs) previously used in the field.Data Sources: PubMed, Cochrane, Scopus, and CINAHL.Review Methods: Publications through March 2025 reporting at least one PROM in maxillofacial trauma patients were included. Study metadata was recorded, and survey instruments were classified as established PROMs or “custom surveys.” Each instrument was analyzed, and key topic domains were characterized. PRISMA‐ScR guidelines were followed.Results: Ninety‐six studies from 23 different countries were identified. They included patients with mandible fractures (n = 38, 39.6%), midface fractures (n = 16, 16.7%), or both (n = 42, 43.8%). There were 73 studies that used 39 unique, established PROMs. These incorporated six key domains: Psychosocial Function (n = 32, 82.1%), Facial Function (n = 13, 33.3%), Facial Appearance (n = 9, 23.1%), Pain (n = 15, 38.5%), Daily Tasks (n = 14, 35.9%), and Satisfaction with Outcome (n = 5, 12.8%). The most common instruments were the Hospital Anxiety and Depression Scale (HADS), Oral Health Impact Profile (OHIP‐14), Mandible Function Impairment Questionnaire (MFIQ), and the Short Form (SF) survey. Forty studies developed at least one custom survey question. These were more likely to address Facial Function (n = 23, 57.5%), Pain (n = 20, 50%), Facial Appearance (n = 15, 37.5%), and Satisfaction with Outcome (n = 13, 32.5%).Conclusion: PROMs used in maxillofacial trauma research are heterogeneous. Most address psychosocial function while only a minority address facial function and appearance. The six key domains identified here may be used to guide the development of novel PROMs.
- 14 May 2024
- Published by Georg Thieme Verlag KG in Facial Plastic Surgery
- Vol. 41 (03) , 319-326
Risk Factors for Missed Follow-up Appointments among Facial Trauma Patients
A retrospective case–control study was performed to characterize the rate of missed follow-up appointments after facial trauma and identify associated risk factors.Follow-up appointments for facial trauma over a 3-month period at a single, safety net hospital were analyzed. Appointment-specific, sociodemographic, trauma, and management data were compared between cases (missed appointments) and controls (attended appointments). Univariate testing and multivariable logistic regression were employed.A total of 116 cases and 259 controls were identified, yielding a missed appointment rate of 30.9% (116/375). Missed appointments were significantly associated with initial clinic appointments compared to return visits (odds ratio [OR] 2.21 [1.38–3.54]), afternoon visits compared to morning (OR 3.14 [1.94–5.07]), lack of private health insurance (OR 2.91 [1.68–5.18]), and presence of midface fractures (OR 2.04 [1.28–3.27]). Missed appointments were negatively associated with mandible fractures (OR 0.56 [0.35–0.89]), surgical management (OR 0.48 [0.30–0.77]), and the presence of nonremovable hardware (OR 0.39 [0.23–0.64]). Upon multivariable logistic regression, missed appointments remained independently associated with afternoon visits (adjusted OR [aOR] 1.95 [1.12–3.4]), lack of private health insurance (aOR 2.73 [1.55–4.8]), and midface fractures (aOR 2.09 [1.21–3.59]).Nearly one-third of facial trauma patients missed follow-up appointments, with the greatest risk among those with afternoon appointments, lacking private health insurance, and with midface fractures.
- 14 May 2024
- Published by Georg Thieme Verlag KG in Facial Plastic Surgery
- Vol. 41 (03) , 319-326
Risk Factors for Missed Follow-up Appointments among Facial Trauma Patients
A retrospective case–control study was performed to characterize the rate of missed follow-up appointments after facial trauma and identify associated risk factors.Follow-up appointments for facial trauma over a 3-month period at a single, safety net hospital were analyzed. Appointment-specific, sociodemographic, trauma, and management data were compared between cases (missed appointments) and controls (attended appointments). Univariate testing and multivariable logistic regression were employed.A total of 116 cases and 259 controls were identified, yielding a missed appointment rate of 30.9% (116/375). Missed appointments were significantly associated with initial clinic appointments compared to return visits (odds ratio [OR] 2.21 [1.38–3.54]), afternoon visits compared to morning (OR 3.14 [1.94–5.07]), lack of private health insurance (OR 2.91 [1.68–5.18]), and presence of midface fractures (OR 2.04 [1.28–3.27]). Missed appointments were negatively associated with mandible fractures (OR 0.56 [0.35–0.89]), surgical management (OR 0.48 [0.30–0.77]), and the presence of nonremovable hardware (OR 0.39 [0.23–0.64]). Upon multivariable logistic regression, missed appointments remained independently associated with afternoon visits (adjusted OR [aOR] 1.95 [1.12–3.4]), lack of private health insurance (aOR 2.73 [1.55–4.8]), and midface fractures (aOR 2.09 [1.21–3.59]).Nearly one-third of facial trauma patients missed follow-up appointments, with the greatest risk among those with afternoon appointments, lacking private health insurance, and with midface fractures.
- 22 May 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (5) , 756-765
A prospective evaluation of neck and shoulder function following treatments of early‐stage human papillomavirus‐associated oropharynx cancer
Objectives: To compare post‐treatment neck and shoulder function between human papillomavirus‐associated oropharynx squamous cell carcinoma (HPV + OPSCC) treatments.Design: Prospective, repeated‐measures study.Setting: Tertiary care center.Participants: Treatment‐naïve patients with American Joint Committee on Cancer eighth edition stage T0‐3/N0‐2 HPV+OPSCC.Main Outcome Measures: Patients completed the Neck Dissection Impairment Index (NDII) pre‐treatment and 3‐months and 1‐year post‐treatment. The NDII assesses 10 neck and shoulder functions scored 0–5 (total score 0–100), with higher scores suggesting better function.Results: A total of 106 patients underwent: surgery alone (SA, n = 46, 43%), surgery with adjuvant radiation ± chemotherapy (S + a[C]XRT, n = 18, 17%), or definitive radiation ± chemotherapy (d[C]XRT, n = 42, 40%). cTN classification and pre‐treatment NDII scores did not differ between groups. SA patients reported worsened 3‐month post‐treatment versus pre‐treatment self‐care (4.6 vs. 5.0), lifting light (4.6 vs. 5.0) and heavy (4.2 vs. 4.8) objects, overhead reach (4.5 vs. 4.9), activity (4.5 vs. 4.9), socialization (4.7 vs. 4.9), recreation (4.6 vs. 4.9), and overall score (86.8 vs. 95.3) (all p < 0.05). One‐year post‐treatment scores (n = 34) were no different than pre‐treatment in all domains. S + a[C]XRT patients reported worsened 3‐month versus pre‐treatment stiffness (4.0 vs. 4.8), lifting heavy objects (3.8 vs. 4.9), overhead reach (4.2 vs. 4.9), socialization (4.6 vs. 5.0), recreation (4.4 vs. 4.9) and overall score (82.4 vs. 96.0) (all p < 0.05). One‐year post‐treatment scores (n = 13) were no different than pre‐treatment in all domains. d[C]XRT patients reported worsened 3‐month versus pre‐treatment difficulty lifting heavy objects (4.3 vs. 4.7) and recreation (4.3 vs. 4.7). One‐year posttreatment scores (n = 21) were no different than pre‐treatment in all domains.Conclusion: HPV + OPSCC patients may experience mild shoulder/neck dysfunction 3 months after treatment that usually resolves by 1 year, independent of treatment modality.
- 22 May 2023
- Published by Wiley in Clinical Otolaryngology
- Vol. 48 (5) , 756-765
A prospective evaluation of neck and shoulder function following treatments of early‐stage human papillomavirus‐associated oropharynx cancer
Objectives: To compare post‐treatment neck and shoulder function between human papillomavirus‐associated oropharynx squamous cell carcinoma (HPV + OPSCC) treatments.Design: Prospective, repeated‐measures study.Setting: Tertiary care center.Participants: Treatment‐naïve patients with American Joint Committee on Cancer eighth edition stage T0‐3/N0‐2 HPV+OPSCC.Main Outcome Measures: Patients completed the Neck Dissection Impairment Index (NDII) pre‐treatment and 3‐months and 1‐year post‐treatment. The NDII assesses 10 neck and shoulder functions scored 0–5 (total score 0–100), with higher scores suggesting better function.Results: A total of 106 patients underwent: surgery alone (SA, n = 46, 43%), surgery with adjuvant radiation ± chemotherapy (S + a[C]XRT, n = 18, 17%), or definitive radiation ± chemotherapy (d[C]XRT, n = 42, 40%). cTN classification and pre‐treatment NDII scores did not differ between groups. SA patients reported worsened 3‐month post‐treatment versus pre‐treatment self‐care (4.6 vs. 5.0), lifting light (4.6 vs. 5.0) and heavy (4.2 vs. 4.8) objects, overhead reach (4.5 vs. 4.9), activity (4.5 vs. 4.9), socialization (4.7 vs. 4.9), recreation (4.6 vs. 4.9), and overall score (86.8 vs. 95.3) (all p < 0.05). One‐year post‐treatment scores (n = 34) were no different than pre‐treatment in all domains. S + a[C]XRT patients reported worsened 3‐month versus pre‐treatment stiffness (4.0 vs. 4.8), lifting heavy objects (3.8 vs. 4.9), overhead reach (4.2 vs. 4.9), socialization (4.6 vs. 5.0), recreation (4.4 vs. 4.9) and overall score (82.4 vs. 96.0) (all p < 0.05). One‐year post‐treatment scores (n = 13) were no different than pre‐treatment in all domains. d[C]XRT patients reported worsened 3‐month versus pre‐treatment difficulty lifting heavy objects (4.3 vs. 4.7) and recreation (4.3 vs. 4.7). One‐year posttreatment scores (n = 21) were no different than pre‐treatment in all domains.Conclusion: HPV + OPSCC patients may experience mild shoulder/neck dysfunction 3 months after treatment that usually resolves by 1 year, independent of treatment modality.
- Open Access
- 5 March 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 7 (2) , 380-387
Effect of microporous polysaccharide hemospheres on anterolateral thigh free flap donor site complications
Background Postoperative seroma is the most common donor site complication following anterolateral thigh (ALT) free flap harvest for head and neck reconstruction. The utility of novel microporous polysaccharide hemospheres (MPH) has not been studied as a hemostatic agent in this setting. Methods Prospective, single-blind, randomized controlled trial of patients undergoing fasciocutaneous ALT harvest for head and neck reconstruction at a tertiary academic medical center between April 2018 and February 2020. The intervention (MPH) group received 3 g of topical MPH to the ALT donor site prior to closure whereas the control group did not receive application of MPH. Outcomes included total drain output (ml), drain output during postoperative days (POD) 1-3 alone, drain duration (days), and incidence of donor site hematoma, seroma, or infection. Results Twenty-nine patients were randomized to the MPH group and 26 to the control group. For MPH and control groups, mean total drain output was 284.7 +/- 153.0 ml versus 317.9 +/- 177.6 ml (p = .527), mean POD 1-3 drain output alone was 169.3 +/- 88.8 ml versus 157.9 +/- 78.7 ml (p = .749), and drain duration was 5.9 +/- 1.5 days versus 6.5 +/- 1.6 days (p = .144), respectively. There was no significant difference in seroma (p = .733), hematoma (p = .492), or infection (p = 1.000). Drain output was not significantly influenced by gender, age, body weight, or smoking habits. Conclusion MPH administration to ALT free flap donor sites did not significantly improve drain output, hematoma formation, or seroma formation. Level of Evidence 2
- 5 March 2022
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 7 (2) , 380-387
Open AccessEffect of microporous polysaccharide hemospheres on anterolateral thigh free flap donor site complications
Background Postoperative seroma is the most common donor site complication following anterolateral thigh (ALT) free flap harvest for head and neck reconstruction. The utility of novel microporous polysaccharide hemospheres (MPH) has not been studied as a hemostatic agent in this setting. Methods Prospective, single-blind, randomized controlled trial of patients undergoing fasciocutaneous ALT harvest for head and neck reconstruction at a tertiary academic medical center between April 2018 and February 2020. The intervention (MPH) group received 3 g of topical MPH to the ALT donor site prior to closure whereas the control group did not receive application of MPH. Outcomes included total drain output (ml), drain output during postoperative days (POD) 1-3 alone, drain duration (days), and incidence of donor site hematoma, seroma, or infection. Results Twenty-nine patients were randomized to the MPH group and 26 to the control group. For MPH and control groups, mean total drain output was 284.7 +/- 153.0 ml versus 317.9 +/- 177.6 ml (p = .527), mean POD 1-3 drain output alone was 169.3 +/- 88.8 ml versus 157.9 +/- 78.7 ml (p = .749), and drain duration was 5.9 +/- 1.5 days versus 6.5 +/- 1.6 days (p = .144), respectively. There was no significant difference in seroma (p = .733), hematoma (p = .492), or infection (p = 1.000). Drain output was not significantly influenced by gender, age, body weight, or smoking habits. Conclusion MPH administration to ALT free flap donor sites did not significantly improve drain output, hematoma formation, or seroma formation. Level of Evidence 2
- 1 July 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 74 (1) , 203-208
Safety and efficacy of transcarotid artery revascularization in a community hospital
- 1 July 2021
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 74 (1) , 203-208
Safety and efficacy of transcarotid artery revascularization in a community hospital
- 22 June 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (12) , 2713-2718
Surveillance Imaging Following Head and Neck Cancer Treatment and Microvascular Reconstruction
Objectives/Hypothesis: To assess the accuracy and utility of positron emission tomography/computed tomography (PET/CT) compared with magnetic resonance imaging (MRI) for detecting head and neck cancer (HNC) recurrence after microvascular reconstructive surgery.Study Design: Retrospective cohort study.Methods: Analysis of HNC patients who underwent microvascular reconstruction at a single, tertiary academic center following ablative surgery from 1998 to 2015. Forty‐six patients aged 61.4 ± 15.8 years with both PET/CT and MRI examinations were identified. Two radiologists were blinded and interpreted each imaging study. Recurrence certainty scores were determined via continuous (0–100) and Likert (“Likely” to “Unlikely”) scales, with larger values indicating a higher likelihood of recurrence. Pathologic confirmation of recurrence was confirmed in 23 patients (50%).Results: Among those with primary site recurrences, mean recurrence certainty was significantly higher with PET/CT versus MRI on the continuous scale (63.9 vs. 44.4, P = .006). A receiver operating characteristic analysis for predicting primary site recurrence demonstrated a significantly larger area under the curve of 0.79 for PET/CT compared to 0.64 for MRI (P = .044). Categorization of “Likely” primary site recurrence on PET/CT, versus MRI, had higher sensitivity (0.63 vs. 0.40), but lower specificity (0.90 vs. 1.0). MRI demonstrated higher sensitivity (1.0 vs. 0.78) at detecting regional site recurrences.Conclusion: PET/CT demonstrates greater sensitivity than MRI as a surveillance tool for primary site recurrence following microvascular reconstruction where clinical evaluation is hindered by anatomical distortion. Therefore, PET/CT should be pursued as first‐line imaging, with MRI utilized for confirmation of positive imaging findings at the primary site.Level of Evidence: 2 Laryngoscope, 131:2713–2718, 2021
- 22 June 2021
- Published by Wiley in The Laryngoscope
- Vol. 131 (12) , 2713-2718
Surveillance Imaging Following Head and Neck Cancer Treatment and Microvascular Reconstruction
Objectives/Hypothesis: To assess the accuracy and utility of positron emission tomography/computed tomography (PET/CT) compared with magnetic resonance imaging (MRI) for detecting head and neck cancer (HNC) recurrence after microvascular reconstructive surgery.Study Design: Retrospective cohort study.Methods: Analysis of HNC patients who underwent microvascular reconstruction at a single, tertiary academic center following ablative surgery from 1998 to 2015. Forty‐six patients aged 61.4 ± 15.8 years with both PET/CT and MRI examinations were identified. Two radiologists were blinded and interpreted each imaging study. Recurrence certainty scores were determined via continuous (0–100) and Likert (“Likely” to “Unlikely”) scales, with larger values indicating a higher likelihood of recurrence. Pathologic confirmation of recurrence was confirmed in 23 patients (50%).Results: Among those with primary site recurrences, mean recurrence certainty was significantly higher with PET/CT versus MRI on the continuous scale (63.9 vs. 44.4, P = .006). A receiver operating characteristic analysis for predicting primary site recurrence demonstrated a significantly larger area under the curve of 0.79 for PET/CT compared to 0.64 for MRI (P = .044). Categorization of “Likely” primary site recurrence on PET/CT, versus MRI, had higher sensitivity (0.63 vs. 0.40), but lower specificity (0.90 vs. 1.0). MRI demonstrated higher sensitivity (1.0 vs. 0.78) at detecting regional site recurrences.Conclusion: PET/CT demonstrates greater sensitivity than MRI as a surveillance tool for primary site recurrence following microvascular reconstruction where clinical evaluation is hindered by anatomical distortion. Therefore, PET/CT should be pursued as first‐line imaging, with MRI utilized for confirmation of positive imaging findings at the primary site.Level of Evidence: 2 Laryngoscope, 131:2713–2718, 2021